189 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
in section 5.5(b) as the Company's shares are not listed on a specified market.
About RepliCel Life Sciences
RepliCel is a regenerative medicine
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
the symbol P6P2.
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits …
The Company's treatments use autologous cell therapy ("ACT"), one of the most rapidly developing areas of regenerative medicine in developing novel
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
, trading under the symbol RP, and in the United States on the OTCQB, trading under the symbol REPCF.
RepliCel is a regenerative medicine company
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
, trading under the symbol REPCF.
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that treat functional
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
.
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. The diseases currently … use autologous cell therapy ("ACT"), one of the most rapidly developing areas of regenerative medicine in developing novel treatments for numerous
6-K
EX-99.1
u9m24e4d6d5ds7mhrcr
19 Oct 23
Current report (foreign)
1:45pm
6-K
EX-99.1
8i5c7eed 1kagedk95xz
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
6-K
EX-99.2
fufbk
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
8i9g8vd3ddv
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
m7y14pjw27twih
7 Sep 23
Current report (foreign)
12:26pm
6-K
EX-99.2
em9od11y3yljp
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
6-K
EX-99.1
2g9pgsvjxmx5j8
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
EX-99.2
9fg 0i8uyee
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.4
x92khs y75as1hcci5
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.1
d8e4app 9s5
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
1e45iia8bvt80l8f4qli
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
z42hxbdj904a8 u20ya0
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
6-K
EX-99.5
3v6nv6
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.2
sk7nt6m3
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm